We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

WERFEN

Werfen provides diagnostic instruments for critical care and hemostasis to meet the testing needs of medical professi... read more Featured Products: More products

Download Mobile App




PF4 Immunoassays Investigated in Vaccine-Induced Thrombotic Thrombocytopenia

By LabMedica International staff writers
Posted on 07 Jun 2021
Post-vaccination embolic and thrombotic events, also termed vaccine-induced prothrombotic immune thrombocytopenia (VIPIT) or vaccine-induced immune thrombotic thrombocytopenia (VITT) are rare types of blood clotting events that were initially observed in a very small number of people who had previously received the COVID-19 vaccine.

Platelet factor 4 (PF4) is a small cytokine belonging to the CXC chemokine family that is also known as chemokine (C-X-C motif) ligand 4 (CXCL4). More...
This chemokine is released from alpha-granules of activated platelets during platelet aggregation, and promotes blood coagulation by moderating the effects of heparin-like molecules. Due to these roles, it is predicted to play a role in wound repair and inflammation.

Medical Scientists at the Toulouse University Hospital (Toulouse, France) and their colleagues analyzed plasma samples from nine patients (median age, 44 years; seven females, two males) with suspected VITT after vaccination with ChAdOx1 nCoV-19 (AstraZeneca, Cambridge, UK). The most common events were cerebral vein thrombosis (n = 6) and splanchnic vein thrombosis (n = 5). All the patients had severe thrombocytopenia (median platelet count nadir, 29,000/mm3; range, 9 to 61,000) except for one woman with both cerebral vein thrombosis and splanchnic vein thrombosis.

Two rapid immunoassays widely used for the diagnosis of heparin-induced thrombocytopenia, STic Expert HIT (Stago Diagnostica, Asnières-sur-Seine, France) and HemosIL AcuStar HIT-IgG (Instrumentation Laboratory, Bedford, MA, USA) were performed on plasma samples to detect PF4-specific antibodies, and the results were negative in all the patients. Two other rapid tests had been performed in some patients by the referring laboratories and were negative, except in one patient, who had an equivocal result.

The team also tested all plasma samples with three different PF4-specific enzyme-linked immunosorbent assays, variable results were obtained. Significant levels of immunoglobulin (Ig)G antibodies to PF4 were detected in seven patients only by the assay that used PF4–poly(vinyl sulfonate) (PVS) complex as the antigenic target. In addition, optical density values were variable and lower than those previously reported with a similar test. The diagnosis of VITT was confirmed by PF4–serotonin release assay in all seven patients with IgG antibodies to PF4–PVS, whereas a standard serotonin release assay was negative in two patients.

The authors concluded that their results provide further support to show that rapid immunoassays should be avoided in the detection of PF4-specific antibodies in patients with suspected VITT. Therefore, the use of a sensitive, quantitative, immunologic test is strongly recommended, because according to the recently proposed algorithm, nonheparin anticoagulants should be preferred when clinically significant levels of anti-PF4 antibodies are detected. The study was published on May 19, 2021 in The New England Journal of Medicine.


Related Links:
Toulouse University Hospital
AstraZeneca
Stago Diagnostica
Instrumentation Laboratory



Gold Member
Veterinary Hematology Analyzer
Exigo H400
Serological Pipet Controller
PIPETBOY GENIUS
New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
New
DNA/RNA Extraction/Purification Kit
Nucleic Acid Extraction or Purification Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.